Category - Developments

Developments

Ampio board committee conducting internal investigation

An independent special committee of the board of Ampio Pharmaceuticals (NYSE American:AMPE), with the assistance of independent legal counsel, is in the process of conducting an internal investigation that relates to...

May 17, 2022

Developments

Lanier Biotherapeutics to present LNR125 poster at American Thoracic Society

Lanier Biotherapeutics will present a poster demonstrating the ability of its LNR 125 to inhibit Type 2 inflammation in models of asthma caused by both allergy and respiratory viral infection at the American Thoracic...

May 13, 2022

Developments

NeoTX acquires InterX to boost drug discovery

Closely-held NeoTX of Israel has acquired InterX, a drug discovery company utilizing advanced proprietary tools of biomolecular computation for the discovery and design of novel therapeutic molecules based on Nobel...

May 12, 2022

Developments

Check-Cap initiates U.S. pivotal trial of C-Scan

Check-Cap (NASDAQ:CHEK) initiated its U.S. pivotal trial of C-Scan to detect polyps before they become colorectal cancer at the Mayo Clinic in Rochester, Minn. The company has obtained Institutional review board...

May 11, 2022

Developments

MindMed collaborators present positive Phase 2 data of LSD in anxiety

Prof. Matthias Liechti and Dr. Friederike Holze, Mind Medicine’s (NASDAQ:MNMD; NEO:MMED) collaborators at University Hospital Basel presented positive topline data from a Phase 2 placebo-controlled investigator...

May 11, 2022

Developments

Three finalists announced for Bloom Burton Award

The finalists for the 2022 Bloom Burton Award are Frank Baylis, executive chairman, and Kris Shah, president of Baylis Medical Technologies; Pieter Cullis, co-founder and chairman, of Acuitas Therapeutics; and Jan...

May 10, 2022

Developments

Profound Medical nearly doubles Q1 revenue

Profound Medical (NASDAQ:PROF; TSX:PRN) posted revenue of $1.4-million in the first quarter, up 92%, from $711,000 in the year earlier quarter. In the latest period, the company generated $1.02-million from recurring...

May 9, 2022

Developments

iBio demonstrates efficacy of an IL-2 sparing anti-CD25 antibody in cancer

iBio (NYSE American:IBIO) is presenting a poster on IBIO-101, its monoclonal antibody candidate for the treatment of solid tumors, at Frontiers in Cancer Immunotherapy 2022 in New York May 9-11. Preclinical evaluation...

May 9, 2022

Developments

Athira Pharma extends open label extension AD studies with fosgonimeton

Athira Pharma (NASDAQ:ATHA) is extending the length of the current open label extension study for its Phase 3 LIFT-AD and Phase 2 ACT-AD studies of fosgonimeton for the treatment of mild-to-moderate Alzheimer’s...

May 9, 2022

Developments

Rani’s RaniPill wins Fast Company’s 2022 World Changing Ideas Award

Rani Therapeutics (NASDAQ:RANI) took top honors for its RaniPill capsule in the health category of Fast Company‘s 2022 World Changing Ideas. The RaniPill capsule is about the size of a standard fish oil pill...

May 3, 2022

Category - Developments

Ampio board committee conducting internal investigation

Lanier Biotherapeutics to present LNR125 poster at American Thoracic Society

NeoTX acquires InterX to boost drug discovery

Check-Cap initiates U.S. pivotal trial of C-Scan

MindMed collaborators present positive Phase 2 data of LSD in anxiety

Three finalists announced for Bloom Burton Award

Profound Medical nearly doubles Q1 revenue

iBio demonstrates efficacy of an IL-2 sparing anti-CD25 antibody in cancer

Athira Pharma extends open label extension AD studies with fosgonimeton

Rani’s RaniPill wins Fast Company’s 2022 World Changing Ideas Award

General

More